Skip to main content
. 2020 Jan 23;9(2):283. doi: 10.3390/cells9020283

Figure 4.

Figure 4

Immuno-modulation strategies for off-the-shelf clinical use of human pluripotent stem cell-derived beta cells. A universal product can be developed by combining gene editing for different strategies, such as HLA antigen disruption to reduce immunogenicity and insertion of double suicide switches to eliminate proliferative, non-committed progenitors as well as other pancreatic lineages, thereby enriching insulin-secreting beta cells.